EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus

Abdulrahman Mujalli iD, Wesam F Farrash iD, Ahmad A Obaid iD, Anmar A Khan, Riyad A Almaimani iD, Shakir Idris, Mohamed E Elzubier iD, Elshiekh Babiker A Khidir iD, Akhmed Aslam iD, Faisal Minshawi iD, Mohammad A Alobaidy iD, Adel B Alharbi iD und 4 weitere

International Journal of Molecular Sciences · 12.12.2023 · 24 (24) · 17380

DOI: 10.3390/ijms242417380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.12.2023. Verfasst von Abdulrahman Mujalli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arab…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Diabetic Nephropathies, Hyperglycemia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herein, we measured the antidiabetic and nephroprotective effects of the sodium–glucose cotransporter-2 inhibitor (empagliflozin; SGLT2i) and synthetic active vitamin D (paricalcitol; Pcal) mono- and co-therapy against diabetic nephropathy (DN). Fifty mice were assigned into negative (NC) and positive (PC) control, SGLT2i, Pcal, and SGLT2i+Pcal groups. Following establishment of DN, SGLT2i (5.1 mg/kg/day) and/or Pcal (0.5 µg/kg/day) were used in the designated groups (5 times/week/day). DN was affirmed in the PC group by hyperglycaemia, dyslipidaemia, polyuria, proteinuria, elevated urine protein/creatinine ratio, and abnormal renal biochemical parameters. Renal SREBP-1 lipogenic molecule, adipokines (leptin/resistin), pro-oxidant (MDA/H2O2), pro-inflammatory (IL1β/IL6/TNF-α), tissue damage (iNOS/TGF-β1/NGAL/KIM-1), and apoptosis (TUNEL/Caspase-3) markers also increased in the PC group. In contrast, renal lipolytic (PPARα/PPARγ), adiponectin, antioxidant (GSH/GPx1/SOD1/CAT), and anti-inflammatory (IL10) molecules decreased in the PC group. Both monotherapies increased insulin levels and mitigated hyperglycaemia, dyslipidaemia, renal and urine biochemical profiles alongside renal lipid regulatory molecules, inflammation, and oxidative stress. While SGLT2i monotherapy showed superior effects to Pcal, their combination demonstrated enhanced remedial actions related to metabolic control alongside renal oxidative stress, inflammation, and apoptosis. In conclusion, SGLT2i was better than Pcal monotherapy against DN, and their combination revealed better nephroprotection, plausibly by enhanced glycaemic control with boosted renal antioxidative and anti-inflammatory mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsDiabetic NephropathiesHyperglycemiaDyslipidemiasMiceAnimalsGlycemic ControlHydrogen PeroxideInflammationAntioxidantsAnti-Inflammatory AgentsErgocalciferolsBenzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

INOSKIM-1NGALSGLT2 inhibitorTGF-βadipokinesvitamin D

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHydrogen PeroxideAntioxidantsAnti-Inflammatory AgentsparicalcitolErgocalciferolsempagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.
  • Biochemistry Department, Faculty of Medicine, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.
  • Department of Anatomy, Faculty of Medicine, Umm AlQura University, Makkah P.O. Box 7607, Saudi Arabia.
  • Department of Laboratory, Al-Noor Specialist Hospital, Makkah P.O. Box 7607, Saudi Arabia.

ORCID-Profile: Abdulrahman Mujalli, Wesam F Farrash, Ahmad A Obaid, Riyad A Almaimani, Mohamed E Elzubier, Elshiekh Babiker A Khidir, Akhmed Aslam, Faisal Minshawi, Mohammad A Alobaidy, Adel B Alharbi, Hussain A Almasmoum, Khalid Alqethami, Bassem Refaat

Zitieren

APA

Mujalli, A., Farrash, W. F., Obaid, A. A., Khan, A. A., Almaimani, R. A., Idris, S., Elzubier, M. E., Khidir, E. B. A., Aslam, A., Minshawi, F., Alobaidy, M. A., Alharbi, A. B., Almasmoum, H. A., Ghaith, M., Alqethami, K., & Refaat, B. (2023). Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 24(24), 17380. https://doi.org/10.3390/ijms242417380

Vancouver

Mujalli A, Farrash WF, Obaid AA, Khan AA, Almaimani RA, Idris S, et al. Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus. International Journal of Molecular Sciences. 2023;24(24):17380. doi:10.3390/ijms242417380

BibTeX
@article{Mujalli2023,
  author = {Mujalli, Abdulrahman and Farrash, Wesam F and Obaid, Ahmad A and Khan, Anmar A and Almaimani, Riyad A and Idris, Shakir and Elzubier, Mohamed E and Khidir, Elshiekh Babiker A and Aslam, Akhmed and Minshawi, Faisal and Alobaidy, Mohammad A and Alharbi, Adel B and Almasmoum, Hussain A and Ghaith, Mazen and Alqethami, Khalid and Refaat, Bassem},
  title = {Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {24},
  pages = {17380},
  doi = {10.3390/ijms242417380}
}
Kostenlos starten →